Cellular and acellular matrix products (CAMPs) are used to support wound healing and improve outcomes in patients with diabetic lower extremity ulcers (DLEU). Despite clinical use of multiple CAMPs, comparative real-world data between different cellular and acellular products are limited. This retrospective study used a large hospital administrative database to compare clinical and economic outcomes for patients with DLEU treated during hospitalization with a minimally manipulated human umbilical tissue allograft (STRAVIX) versus several acellular CAMPs (aCAMPs).
The analysis employed the Premier PINC AI Healthcare Database to identify hospitalized patients with DLEU who received either STRAVIX or one of four different acellular CAMPs. Each patient’s earliest inpatient encounter during the study period was designated as the index admission for analysis.
To address baseline differences between groups, the investigators applied inverse probability of treatment weighting (IPTW) to balance covariates. After weighting, IPTW-adjusted generalized linear models were used to estimate clinical outcomes (complications, procedures, readmissions) and hospital-related economic outcomes (length of stay, visit costs). The abstract reports methods at a high level; the source did not include additional methodological details in the provided abstract text.
Cohort sizes reported in the abstract were 2,626 hospital patients with DLEU treated with STRAVIX and 10,002 patients treated with aCAMPs. After IPTW adjustment, several outcome differences favored STRAVIX in addition to standard surgical management:
Odds of experiencing an infection reaction after index discharge were significantly lower in the STRAVIX group compared with aCAMP-treated patients (exact odds ratios were not reported in the abstract).
Rates of wound dehiscence following discharge were significantly lower among STRAVIX-treated patients versus those receiving aCAMPs.
Both minor and major amputation outcomes were significantly reduced in the STRAVIX cohort compared with aCAMP patients.
Resource use during follow-up showed reductions for STRAVIX-treated patients: the number of DLEU-related follow-up visits was 17–23% lower, and debridement-related visits were 19–23% lower compared with aCAMP patients.
The incidence of all-cause readmission was 22–25% lower in the STRAVIX group compared to the aCAMP group.
Hospital utilization and costs were also lower with STRAVIX: length of stay days were 3% lower and the cost of all-cause visits was 20–25% lower for STRAVIX-treated patients versus those treated with aCAMPs.
The abstract frames these results as demonstrating improved clinical outcomes and lower resource use in a large real-world dataset when STRAVIX was used in addition to standard surgical management compared with certain acellular CAMPs.
The most clinically relevant outcome differences reported were reductions in postoperative complications and limb-sparing events: fewer infection reactions, less dehiscence, and fewer minor and major amputations in the STRAVIX group. These clinical improvements were accompanied by lower follow-up utilization (fewer wound and debridement visits) and reduced all-cause readmissions, which together corresponded with lower overall hospital-associated costs in the STRAVIX-treated cohort.
The abstract does not provide specific numerical effect sizes (for example, odds ratios or confidence intervals) for each outcome in the text provided here, nor does it provide granular breakdowns by the four aCAMPs evaluated. Detailed statistical output and subgroup analyses, if any, were not included in the abstract text available in the source excerpt.
The source is a medRxiv preprint and has not been peer reviewed; the authors explicitly note this limitation and state the work should not be used to guide clinical practice without further validation. The abstract summarizes methods and key findings but omits detailed statistical estimates and full methodological parameters in the text provided. Any interpretation should account for the observational, retrospective design and potential for residual confounding despite IPTW adjustment.
The authors declare that Jaideep Banerjee, Chien-Cheng Chen, and Tim Styche are employees of Smith & Nephew. The manuscript includes standard author declarations: data were deidentified and HIPAA-compliant, informed consent was not required for the deidentified data, and the study was reported as exempt from Institutional Review Board approval. The authors also indicate adherence to research reporting guidelines, though specific checklist identifiers or trial registration details were not provided in the abstract text.
The abstract states that all data produced in the work are contained within the manuscript. No additional external datasets or code links are reported in the abstract text provided here.